We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





Rapid Antigen COVID-19 Tests Not Keeping Pace with Variants of Concern

By LabMedica International staff writers
Posted on 06 May 2022
Print article
Image: Rapid antigen tests remain a useful tool for detection of COVID-19 (Photo courtesy of Pexels)
Image: Rapid antigen tests remain a useful tool for detection of COVID-19 (Photo courtesy of Pexels)

Rapid antigen tests for the diagnosis of COVID-19 are slightly less accurate than the genetic tests administered by healthcare professionals, although their ease-of-use allows the general public to monitor themselves for COVID-19 infections at home and make timely decisions to help stop the spread. The home tests, however, were developed for use with the original SARS-CoV-2 viral strain that emerged late in 2019. Since then, the virus has evolved countless times, and several viral variants of concern have emerged, including the highly infectious delta and omicron variants that swept across the world. Now a new study suggests that while rapid antigen tests remain a useful tool for the detection of COVID-19 infections, continuous assessment and updating is likely needed in the context of variants of concern.

In the recent study, scientists at the Harvard T.H. Chan School of Public Health (Boston, MA, USA) and Beth Israel Deaconess (Boston, MA, USA) used live virus culture to assess how well four rapid antigen tests are able to detect these COVID variants of concern. Using three strains of cultured live virus, the team assessed differences in the limits of detection (LoD) - the smallest amount of viral antigen detectable at 95% certainty – of four commercially available rapid antigen tests. The researchers found that all four tests were as sensitive to the Omicron variant, if not more, as they were to original SARS-CoV-2 viral strain, known as WA1. Three tests, however, showed less sensitivity to the Delta strain, with only one demonstrating equal detection of all three strains.

“Unlike the sensitive molecular tests that detect multiple SARS-CoV-2 genes, rapid antigen tests target a single viral protein,” said James Kirby, MD, director of the Clinical Microbiology Laboratory at BIDMC. “As the pandemic continues, however, some hypothesize that the performance of available antigen test may vary among the COVID variants of concern.”

“We expect that the observed loss in Delta sensitivity could have resulted in a 20% or more loss of detection in potentially infectious individuals – nevertheless, the most infectious individuals still should have been detected,” added Kirby, also a professor of pathology at Harvard Medical School. “However, our findings suggest that antigen test performance needs to be reevaluated for emerging variants to ensure they still meet the intended public health testing goals of the pandemic.”

Related Links:
Harvard T.H. Chan School of Public Health 
Beth Israel Deaconess 

Platinum Supplier
SARS-CoV-2 Pooling Test
Extensive SARS-CoV-2 Pooling
New
Automatic Hematology Analyzer
BF-7200Plus
New
Silver Supplier
3-Part Diff Hematology Analyzer
Abacus Junior 30
New
SARS-CoV-2 IgG Antibodies Anti-S1 Assay
iRapid SARS-CoV-2 Quant "Neutralizing" Ab

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: Guidance UTI provides personalized results in less than one day from receipt at lab (Photo courtesy of Pathnostics)

Rapid Result Test for Complicated Urinary Tract Infections Proves Superior to Standard Urine Culture

Complicated urinary tract infections (cUTIs) are a significant burden on individual health and healthcare resources that must be diagnosed and treated early and accurately to reduce the risk of poor outcomes.... Read more

Hematology

view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.